Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to T-DXd
Related studies linked through entity extraction aliases.
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
- Status
- RECRUITING
- Phase
- PHASE2
Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
- Status
- RECRUITING
- Phase
- PHASE3
Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib
- Status
- RECRUITING
- Phase
- N/A
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
- Status
- RECRUITING
- Phase
- PHASE1